drugset / Trial / NCT04551170

Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old

NCT04551170

Phase 2 Active not recruiting 34 enrolled Vanderbilt University Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature and resistance to multiple hormones. This phase 2 clinical trial and open-label extension study will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, slow the rate of growth plate closure and decrease hormone resistance in children.

Timeline

Start
2020-07-13
Primary completion
2026-12-31
Completion
2026-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Theophylline Small molecule Oral